Receptor tyrosine kinases as candidate prognostic biomarkers and therapeutic targets in meningioma
Visualizar/abrir
Data
2021Tipo
Assunto
Abstract
Meningioma (MGM) is the most common type of intracranial tumor in adults. The validation of novel prognostic biomarkers to better inform tumor stratification and clinical prognosis is urgently needed. Many molecular and cellular alterations have been described in MGM tumors over the past few years, providing a rational basis for the identification of biomarkers and therapeutic targets. The role of receptor tyrosine kinases (RTKs) as oncogenes, including those of the ErbB family of receptors, ha ...
Meningioma (MGM) is the most common type of intracranial tumor in adults. The validation of novel prognostic biomarkers to better inform tumor stratification and clinical prognosis is urgently needed. Many molecular and cellular alterations have been described in MGM tumors over the past few years, providing a rational basis for the identification of biomarkers and therapeutic targets. The role of receptor tyrosine kinases (RTKs) as oncogenes, including those of the ErbB family of receptors, has been well established in several cancer types. Here, we review histological, molecular, and clinical evidence suggesting that RTKs, including the epidermal growth factor receptor (EGFR, ErbB1), as well as other members of the ErbB family, may be useful as biomarkers and therapeutic targets in MGM. ...
Contido em
International journal of molecular sciences. Basel. Vol. 22, no. 21 (Nov. 2021), 11352, 15 p.
Origem
Estrangeiro
Coleções
-
Artigos de Periódicos (39774)Ciências Biológicas (3109)
Este item está licenciado na Creative Commons License